Jeffrey Eisele - 29 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
29 Jan 2024
Transactions value $
-$81,524
Form type
4
Filing time
31 Jan 2024, 16:23:50 UTC
Previous filing
24 Jan 2024
Next filing
27 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$17,894 -279 -0.48% $64.14 58,179 29 Jan 2024 Direct F1
transaction APLS Common Stock Sale -$63,629 -971 -1.67% $65.53 57,208 30 Jan 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024.
F2 This is a scheduled sale from an established 10b5-1 plan.